Arctic Bioscience – 12-month data confirm potential for HRO350 in mild-to-moderate psoriasis

12-month readout of the HeROPA phase 2b clinical trial shows potential through key secondary endpoint PGA 0/1, where the per protocol population approaches significance (p = 0.07) after one year of treatment. Relevant subgroups show statistical significance (p < 0.05).

Importantly, HRO350 was well tolerated throughout the study, with no safety concerns or drug-related serious adverse events reported.

While the primary endpoint (PASI50 at 26 weeks) in the 52-week placebo-controlled study was not met due to an unexpectedly high placebo response, the overall data support the potential of HRO350.

Arctic Bioscience strongly believe there is a major market potential for HRO350 in mild-to-moderate psoriasis and will seek partnerships for further development.

“We are encouraged by the efficacy and safety profile of HRO350. These results reinforce our belief in the potential of this asset to address chronic conditions like psoriasis. We will now evaluate strategic opportunities for further development and regulatory engagement for HRO350”, says CEO, Christer L. Valderhaug.

"We saw that many patients benefited from taking part in the study, and at Haukeland we have skilled study nurses who have provided the patients with good care. There is an effect in the treatment groups, the mystery is placebo, which we need to understand better in order to design a next study with HRO350". says Professor Ingeborg Bachmann, principal investigator in the HeROPA study.

“A challenge with analyzing these data has been the high placebo rate. Numerically, HRO350 is better than placebo on key secondary endpoints, and a consistent trend can be seen across endpoints for the patients who remained on treatment for a full year”, says Medical Director, Runhild Gammelsæter.

Invitation to webcast

Arctic Bioscience will host a webcast tomorrow 2nd of July 2025 at 10:00 CET, to present the results from the HeROPA 12-month read-out.

The webcast will be hosted by CEO Christer L. Valderhaug and Medical Director Runhild Gammelsæter. Following the presentation, it will be open to questions from the audience.

Webcast details:

Date: Wednesday 2nd of July 2025

Time: 10:00 CET

Format: Webcast and Q&A

Language: Norwegian/English

The presentation can be accessed through the link below:

https://events.teams.microsoft.com/event/db1c7d34-fe2e-4d53-ad72-41a906b61709@ce618813-5158-40b5-b6d0-2f2cd3f39b20

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

About Arctic Bioscience

Arctic Bioscience is a biotech company developing and commercializing pharmaceutical and nutraceutical products based on unique bioactive marine compounds.

The company is developing HRO350 – a novel oral drug candidate. HRO350 is being developed for treatment of patients with mild-to-moderate psoriasis. This is a large patient group in need of new effective medicines with beneficial safety profile.

Nutraceuticals from Arctic Bioscience are sold globally as bulk ingredients as well as finished goods under the ROMEGA® brand.

Arctic Bioscience is led by a highly skilled team of talents with diverse and highly relevant background.

For more information, please contact:

Christer L. Valderhaug

CEO

Mobile: +47 920 84 601

E-mail: christer@arctic-bioscience.com

Läs mer på Cision